Compare Neurocrine Biosciences Inc (NBIX) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $121.92 (market cap $1.45B). The key difference: Neurocrine Biosciences Inc is far larger — about 9.9× Direxion NASDAQ 100 Equal Weighted Index Shares's market cap, and Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Direxion NASDAQ 100 Equal Weighted Index Shares for 48 Days on average.
| NBIX | QQQE | |
|---|---|---|
Market Cap | $14.36B | $1.45B |
Volume | 1,237,180 | 323,568 |
Sector | Health | Broad Market / Factor |
52-Week High | $185.50 | $124.69 |
52-Week Low | $123.10 | $96.06 |
Typical Hold Time | 23 Days | 48 Days |
Enterprise Value | $14.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
QQQE, the Direxion NASDAQ-100 Equal Weighted Index ETF, trades at $121.03, down 0.71% on the day. The technical outlook is bullish based on moving averages, with oscillators neutral. Recent news highlights its equal-weight strategy reducing technology concentration compared to market-cap weighted peers. The fund provides diversified exposure to large-cap growth stocks within the Nasdaq-100 index.
The outlook for QQQE is supported by its tactical appeal as an equal-weight alternative, though it carries risks tied to Nasdaq performance and sector concentration. Investor sentiment appears cautiously optimistic given recent favorable coverage comparing it to QQQ. The absence of traditional valuation ratios is typical for an ETF tracking an index.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
